TｅxtA/50９Ｗorｄs/Tｉmｅforrｅａdｉｎg:3.5ｍinｕteｓ/ＴｈeＥｕｒopeanCommiｓｓionsａiｄoｎThursdayitwouｌｄtｏughｅnｔｈerｅgｕlaｔiｏｎｏfmedicalｄeｖicesasaｒesultｏfconcernsraisedbｙbreａsｔimpｌantsｐrｏdｕｃeｄbｙthedｅfuncｔＦrenchcompanyPＩP,ｅvenａsascｉentｉficexpｅrtrevｉeｗitｏrdeｒedｃoncludｅdｔheｒｅwascurreｎtｌy“iｎsufficiｅntevideｎce”thatwoｍenuｓinｇｉtｓpｒoｄuｃtsfaceｄgreaterhealｔhrisｋsthａnｏtherｓ.JohｎDalli,ｈealｔhaｎdcoｎsumeｒpolicycｏmmissｉoner,plｅdgedtoexaminesurveiｌlanｃeaｎdｏｐerationofthe“ｎｏｔiｆiedboｄies”thａtscrｕtinisemｅｄicalｄevicesacrｏssthｅＥUinaｃurrentrevieｗoｆｌegislation,stｒeｓsiｎg:“Thecapａcityｔodｅｔｅctaｎdminimｉｓetheriskoｆfrａuｄｍustbeｉｎcreaｓeｄ.”HiscｏｍmｅntsfoｌlｏwedanofficialｒｅｐｏrtｒｅlｅasedｏnWeｄneｓｄayinFraｎceｔhatｃallｅdｆorｎatioｎalandEU－wｉdeｃo-ｏperaｔｉｏｎincｌudｉngｒaｎdomiｎｓpｅctionsandsａmpliｎgofmｅdｉcaldeviｃeｓtopreventarepeatｏfｔhefraudulentｕｓeofｓubsｔandardnon-mediｃal-gｒadesｉlｉconebｙＰIPinｉmpｌanｔssolｄtoupto４00,00０wｏｍenarｏｕndthewｏrld.ＸaviｅrBertraｎd,Fraｎce’ｓminｉstｅroｆｈｅaｌtｈ,caｌlｅdforeｎhanｃedａctioｎiｎFraｎceandａcrossEurｏpeinthewakeoｆthestｕｄy,ｗhｉｃｈhiｇhlighｔedthatAfssaps,theFｒencｈmeｄｉｃalregｕlａtor,ｄｉdｎｏtinｓpeｃtＰIPfrom20０1unｔiｌａｔip－oｆfｌｅdofficiａlstoinsｐectａnｄcｌosedowｎｔhecoｍpanｙin２0１0.Jｅａn-ClaudeＭas，ｉtsfoundｅｒ,iｓundｅrｐｏliceinvｅｓtigaｔioｎｆormansｌaughteｒ．Mr．ＢerｔrandhaｓplｅdgeｄｔｏhｉremｏrehealｔhiｎspectoｒsaｎdｕnｄeｒｔakerandoｍchｅcksonｍediｃaｌdevｉceｃｏmpanieｓfolloｗｉｎｇgrｏｗiｎgconcernsoveritsregｕlａtorｙsystemhighlighｔedbythewideｓｐｒeaduseoｆPIP’ssubstaｎdarｄbｒeaｓtｉmplants.AFrｅｎchdecisiｏnａttheeｎdoflasｔyeａrtooｆｆeraｌｌｗｏmenｆｒeeremovaloｆＰIＰimplaｎｔstrｉggereｄsimｉｌarｐｒｏposalｓｉｎtheUＫ,GermａnyandthｅCzｅｃhRepubliｃandhａshｅlｐedsｐaｒkaｆreshdebａｔeｏvｅrtoｕgｈerEUregulationofmedicaldevices,whichareｓubjｅcttofarｌｅｓｓsｃrutinyｔhanpharmaceｕticａls．Ｈowevｅr，aｒｅviｅwｒeleaｓｅdonＴhuｒsｄａyｂyｔheEＵ’sownSciｅｎｔiｆicＣommiｔteeonEｍerｇiｎgaｎdNｅwlyIｄentｉfｉedHｅalthRiskｓconcluded:“Ｂreａstimｐlantsｃanfaｉl,ｒeｇardlessofｍanufacturer，andthｅprobａｂilｉtｙoｆfaｉlurｅincrｅasesｗitｈtimeｓiｎcｅiｍｐlantａｔion.Inmｏsｔcasｅs,brｅasｔimｐlaｎｔfａiｌｕrｅappeaｒsｔｏｂewｉtｈoutidenｔｉfiａbleheaｌthconｓｅqueｎcesforthepatientwiththeｅxceptiｏｎoｆpoｓsiｂlｅｌｏｃａlｃomplｉｃatioｎｓ．”Itsｔresｓｅdthａtliｍｉteｄdataｍeanｔthａtwｈileｔherｅｗａｓnolinkbｅtweｅnbreａｓtimｐｌantsandcancer,thereｗaｓaｎeｅdforfurｔｈeｒwｏrkｔｏuｎdｅrstaｎdthespeciｆｉcｒiｓksfromtｈePIＰproducts.Mr.ＢｅｒtｒandhａsｅnｄorｓｅdｃａllｓfｏｒapaｒｌｉamentａryinquｉryｉnFｒａnｃeaswellaｓａreportfromthecouｎtｒy’ssoｃiａlａｆfａirsｉnｓpeｃtorａte，mirroringsimｉlaｒmoｖeｓtｈａtｌedtotｏuｇhnewrｅqｕｉreｍｅｎtsforthepharmaｃeuticａlｉndｕstrｙintroducedlａstyearinthｅｗaｋeｏfconcernsａboutServｉｅｒ’sdrugMediaｔor.Ｍedｉｃaldevｉｃｅmanufacｔurｅrsｈavecａｌｌeｄｆｏrrｅformstoensurｅｔhaｔtheｎationａl“notiｆiedbｏdieｓ”whichauｄitｔｈｅｑuaｌｉtyoｆtheirprodｕctsａcrｏsｓEuｒoｐeareｏfacoｎsistentlyｈｉgｈsｔaｎdard,whｉlｅcautioninｇthattoｕghnｅwｒeguｌａtoryreqｕiｒｅmentscouｌdhａｒmtheＥU’ｓcｏ...
